Allworth Financial’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.32K Buy
117
+6
+5% +$643 ﹤0.01% 4103
2026
Q2
$10.3K Hold
111
– – ﹤0.01% 3692
2026
Q1
$6.08K Buy
111
+11
+11% +$664 ﹤0.01% 3840
2025
Q4
$6.53K Hold
100
– – ﹤0.01% 3551
2025
Q3
$8.17K Hold
100
– – ﹤0.01% 3268
2025
Q2
$3.58K Hold
100
– – ﹤0.01% 3448
2025
Q1
$4.46K Buy
+100
New +$3.6K ﹤0.01% 2823

Other funds holding MNPR

Allworth Financial's MNPR Position: Q3 2026 in Review

Allworth Financial increased its Monopar Therapeutics (MNPR) stake by 5.4% in Q3 2026, buying an estimated $643 and bringing the position to 117 shares worth $9.32K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.

Allworth Financial first reported a position in MNPR in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.3K in Q2 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Allworth Financial held 117 shares of Monopar Therapeutics worth $9.32K as of Q3 2026.
  • Allworth Financial bought 6 Monopar Therapeutics shares in Q3 2026, an estimated $643.
  • Monopar Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #4103 holding.
  • Allworth Financial first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Allworth Financial's Monopar Therapeutics position peaked at $10.3K in Q2 2026.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.